Alkem Laboratories Limited has informed the Exchange about Updates on Acquisition.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Midcap 150 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alkem Laboratories' wholly-owned subsidiary, Alkem Medtech Private Limited, has executed a Share Purchase Agreement (SPA) on 6th March 2026 to acquire between 51% and 55% of the equity share capital of Occlutech Holding AG, a Switzerland-based company. This follows the company's earlier intimation dated 13th February 2026 about its intent to acquire a majority stake in Occlutech. The transaction is being carried out through a subsidiary rather than directly by the listed entity, and is being done with the selling shareholders via a private SPA. Financial details of the deal have not been disclosed in this filing.
This is a positive strategic move for Alkem Laboratories, expanding its medical devices portfolio into the European market through its medtech subsidiary. Shareholders should watch for further disclosures on deal valuation, completion timelines, and any required regulatory or open offer implications.